Loading…
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease
ABSTRACT Background Neurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration. Objectives To determine whether plasma and CSF NfL (1) associate with motor or cognitive status in Parkinson's disease (PD) and (2) predict future motor or cognitive decline in PD. Methods...
Saved in:
| Published in: | Movement disorders 2021-12, Vol.36 (12), p.2945-2950 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5099-9738a61298abdb667080dbf71cf82364a2e5ff98d53c4bc0a9191e0f1cb4cd4c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5099-9738a61298abdb667080dbf71cf82364a2e5ff98d53c4bc0a9191e0f1cb4cd4c3 |
| container_end_page | 2950 |
| container_issue | 12 |
| container_start_page | 2945 |
| container_title | Movement disorders |
| container_volume | 36 |
| creator | Aamodt, Whitley W. Waligorska, Teresa Shen, Junchao Tropea, Thomas F. Siderowf, Andrew Weintraub, Daniel Grossman, Murray Irwin, David Wolk, David A. Xie, Sharon X. Trojanowski, John Q. Shaw, Leslie M. Chen‐Plotkin, Alice S. |
| description | ABSTRACT
Background
Neurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration.
Objectives
To determine whether plasma and CSF NfL (1) associate with motor or cognitive status in Parkinson's disease (PD) and (2) predict future motor or cognitive decline in PD.
Methods
Six hundred and fifteen participants with neurodegenerative diseases, including 152 PD and 200 healthy control participants, provided a plasma and/or cerebrospinal fluid (CSF) NfL sample. Diagnostic groups were compared using the Kruskal−Wallis rank test. Within PD, cross‐sectional associations between NfL and Unified Parkinson's Disease Rating Scale Part III (UPDRS‐III) and Mattis Dementia Rating Scale (DRS‐2) scores were assessed by linear regression; longitudinal analyses were performed using linear mixed‐effects models and Cox regression.
Results
Plasma and CSF NfL levels correlated substantially (Spearman r = 0.64, P |
| doi_str_mv | 10.1002/mds.28779 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8688198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2569373005</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5099-9738a61298abdb667080dbf71cf82364a2e5ff98d53c4bc0a9191e0f1cb4cd4c3</originalsourceid><addsrcrecordid>eNp1kUtvEzEUhS0EomlgwR9AltjAYlo_xh57g1QSXlJ4SIW15fFcJy4zdrEzrfrvMaRUgMTqLs6nT-fqIPSEkhNKCDudhnLCVNfpe2hBBaeNYqK7jxZEKdFwqsQROi7lghBKBZUP0RFvW0W45At0_hHmnHwY7QRxjzdhu9vj1c6GiG3BFr8KabL5G2TsU8artI1hH64Ar8GNIQKu3Oeah1hSxOtQwBZ4hB54OxZ4fHuX6Oub119W75rNp7fvV2ebxgmidaM7rqykTCvbD72UHVFk6H1HnVeMy9YyEN5rNQju2t4Rq6mmQDx1feuG1vElennwXs79BIOrD2Q7msscauUbk2wwfycx7Mw2XRkllaJaVcHzW0FO32coezOF4mAcbYQ0F8OE1LzjhIiKPvsHvUhzjvU9wySlhPGuskv04kC5nErJ4O_KUGJ-TmXqVObXVJV9-mf7O_L3NhU4PQDXYYSb_5vMh_X5QfkDt1Wd8w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2611023769</pqid></control><display><type>article</type><title>Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Aamodt, Whitley W. ; Waligorska, Teresa ; Shen, Junchao ; Tropea, Thomas F. ; Siderowf, Andrew ; Weintraub, Daniel ; Grossman, Murray ; Irwin, David ; Wolk, David A. ; Xie, Sharon X. ; Trojanowski, John Q. ; Shaw, Leslie M. ; Chen‐Plotkin, Alice S.</creator><creatorcontrib>Aamodt, Whitley W. ; Waligorska, Teresa ; Shen, Junchao ; Tropea, Thomas F. ; Siderowf, Andrew ; Weintraub, Daniel ; Grossman, Murray ; Irwin, David ; Wolk, David A. ; Xie, Sharon X. ; Trojanowski, John Q. ; Shaw, Leslie M. ; Chen‐Plotkin, Alice S.</creatorcontrib><description>ABSTRACT
Background
Neurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration.
Objectives
To determine whether plasma and CSF NfL (1) associate with motor or cognitive status in Parkinson's disease (PD) and (2) predict future motor or cognitive decline in PD.
Methods
Six hundred and fifteen participants with neurodegenerative diseases, including 152 PD and 200 healthy control participants, provided a plasma and/or cerebrospinal fluid (CSF) NfL sample. Diagnostic groups were compared using the Kruskal−Wallis rank test. Within PD, cross‐sectional associations between NfL and Unified Parkinson's Disease Rating Scale Part III (UPDRS‐III) and Mattis Dementia Rating Scale (DRS‐2) scores were assessed by linear regression; longitudinal analyses were performed using linear mixed‐effects models and Cox regression.
Results
Plasma and CSF NfL levels correlated substantially (Spearman r = 0.64, P < 0.001); NfL was highest in neurocognitive disorders. PD participants with high plasma NfL were more likely to develop incident cognitive impairment (HR 5.34, P = 0.005).
Conclusions
Plasma NfL is a useful prognostic biomarker for PD, predicting clinical conversion to mild cognitive impairment or dementia. © 2021 International Parkinson and Movement Disorder Society</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.28779</identifier><identifier>PMID: 34480363</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Biomarkers ; Biomarkers - cerebrospinal fluid ; Cerebrospinal fluid ; Cognition ; Cognitive ability ; Cognitive Dysfunction - cerebrospinal fluid ; Cognitive Dysfunction - diagnosis ; Cognitive Dysfunction - etiology ; Cross-Sectional Studies ; Dementia ; Dementia disorders ; Disease Progression ; Humans ; Intermediate Filaments - metabolism ; Medical prognosis ; Movement disorders ; Neurodegeneration ; Neurodegenerative diseases ; neurofilament light chain protein ; NfL ; Parkinson Disease - complications ; Parkinson Disease - diagnosis ; Parkinson's disease ; Plasma ; prognosis ; Regression analysis</subject><ispartof>Movement disorders, 2021-12, Vol.36 (12), p.2945-2950</ispartof><rights>2021 International Parkinson and Movement Disorder Society</rights><rights>2021 International Parkinson and Movement Disorder Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5099-9738a61298abdb667080dbf71cf82364a2e5ff98d53c4bc0a9191e0f1cb4cd4c3</citedby><cites>FETCH-LOGICAL-c5099-9738a61298abdb667080dbf71cf82364a2e5ff98d53c4bc0a9191e0f1cb4cd4c3</cites><orcidid>0000-0003-0766-1496 ; 0000-0002-5599-5098 ; 0000-0003-0633-7168 ; 0000-0001-8130-2809 ; 0000-0002-3387-2038</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34480363$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aamodt, Whitley W.</creatorcontrib><creatorcontrib>Waligorska, Teresa</creatorcontrib><creatorcontrib>Shen, Junchao</creatorcontrib><creatorcontrib>Tropea, Thomas F.</creatorcontrib><creatorcontrib>Siderowf, Andrew</creatorcontrib><creatorcontrib>Weintraub, Daniel</creatorcontrib><creatorcontrib>Grossman, Murray</creatorcontrib><creatorcontrib>Irwin, David</creatorcontrib><creatorcontrib>Wolk, David A.</creatorcontrib><creatorcontrib>Xie, Sharon X.</creatorcontrib><creatorcontrib>Trojanowski, John Q.</creatorcontrib><creatorcontrib>Shaw, Leslie M.</creatorcontrib><creatorcontrib>Chen‐Plotkin, Alice S.</creatorcontrib><title>Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease</title><title>Movement disorders</title><addtitle>Mov Disord</addtitle><description>ABSTRACT
Background
Neurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration.
Objectives
To determine whether plasma and CSF NfL (1) associate with motor or cognitive status in Parkinson's disease (PD) and (2) predict future motor or cognitive decline in PD.
Methods
Six hundred and fifteen participants with neurodegenerative diseases, including 152 PD and 200 healthy control participants, provided a plasma and/or cerebrospinal fluid (CSF) NfL sample. Diagnostic groups were compared using the Kruskal−Wallis rank test. Within PD, cross‐sectional associations between NfL and Unified Parkinson's Disease Rating Scale Part III (UPDRS‐III) and Mattis Dementia Rating Scale (DRS‐2) scores were assessed by linear regression; longitudinal analyses were performed using linear mixed‐effects models and Cox regression.
Results
Plasma and CSF NfL levels correlated substantially (Spearman r = 0.64, P < 0.001); NfL was highest in neurocognitive disorders. PD participants with high plasma NfL were more likely to develop incident cognitive impairment (HR 5.34, P = 0.005).
Conclusions
Plasma NfL is a useful prognostic biomarker for PD, predicting clinical conversion to mild cognitive impairment or dementia. © 2021 International Parkinson and Movement Disorder Society</description><subject>Biomarkers</subject><subject>Biomarkers - cerebrospinal fluid</subject><subject>Cerebrospinal fluid</subject><subject>Cognition</subject><subject>Cognitive ability</subject><subject>Cognitive Dysfunction - cerebrospinal fluid</subject><subject>Cognitive Dysfunction - diagnosis</subject><subject>Cognitive Dysfunction - etiology</subject><subject>Cross-Sectional Studies</subject><subject>Dementia</subject><subject>Dementia disorders</subject><subject>Disease Progression</subject><subject>Humans</subject><subject>Intermediate Filaments - metabolism</subject><subject>Medical prognosis</subject><subject>Movement disorders</subject><subject>Neurodegeneration</subject><subject>Neurodegenerative diseases</subject><subject>neurofilament light chain protein</subject><subject>NfL</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson Disease - diagnosis</subject><subject>Parkinson's disease</subject><subject>Plasma</subject><subject>prognosis</subject><subject>Regression analysis</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kUtvEzEUhS0EomlgwR9AltjAYlo_xh57g1QSXlJ4SIW15fFcJy4zdrEzrfrvMaRUgMTqLs6nT-fqIPSEkhNKCDudhnLCVNfpe2hBBaeNYqK7jxZEKdFwqsQROi7lghBKBZUP0RFvW0W45At0_hHmnHwY7QRxjzdhu9vj1c6GiG3BFr8KabL5G2TsU8artI1hH64Ar8GNIQKu3Oeah1hSxOtQwBZ4hB54OxZ4fHuX6Oub119W75rNp7fvV2ebxgmidaM7rqykTCvbD72UHVFk6H1HnVeMy9YyEN5rNQju2t4Rq6mmQDx1feuG1vElennwXs79BIOrD2Q7msscauUbk2wwfycx7Mw2XRkllaJaVcHzW0FO32coezOF4mAcbYQ0F8OE1LzjhIiKPvsHvUhzjvU9wySlhPGuskv04kC5nErJ4O_KUGJ-TmXqVObXVJV9-mf7O_L3NhU4PQDXYYSb_5vMh_X5QfkDt1Wd8w</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Aamodt, Whitley W.</creator><creator>Waligorska, Teresa</creator><creator>Shen, Junchao</creator><creator>Tropea, Thomas F.</creator><creator>Siderowf, Andrew</creator><creator>Weintraub, Daniel</creator><creator>Grossman, Murray</creator><creator>Irwin, David</creator><creator>Wolk, David A.</creator><creator>Xie, Sharon X.</creator><creator>Trojanowski, John Q.</creator><creator>Shaw, Leslie M.</creator><creator>Chen‐Plotkin, Alice S.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0766-1496</orcidid><orcidid>https://orcid.org/0000-0002-5599-5098</orcidid><orcidid>https://orcid.org/0000-0003-0633-7168</orcidid><orcidid>https://orcid.org/0000-0001-8130-2809</orcidid><orcidid>https://orcid.org/0000-0002-3387-2038</orcidid></search><sort><creationdate>202112</creationdate><title>Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease</title><author>Aamodt, Whitley W. ; Waligorska, Teresa ; Shen, Junchao ; Tropea, Thomas F. ; Siderowf, Andrew ; Weintraub, Daniel ; Grossman, Murray ; Irwin, David ; Wolk, David A. ; Xie, Sharon X. ; Trojanowski, John Q. ; Shaw, Leslie M. ; Chen‐Plotkin, Alice S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5099-9738a61298abdb667080dbf71cf82364a2e5ff98d53c4bc0a9191e0f1cb4cd4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarkers</topic><topic>Biomarkers - cerebrospinal fluid</topic><topic>Cerebrospinal fluid</topic><topic>Cognition</topic><topic>Cognitive ability</topic><topic>Cognitive Dysfunction - cerebrospinal fluid</topic><topic>Cognitive Dysfunction - diagnosis</topic><topic>Cognitive Dysfunction - etiology</topic><topic>Cross-Sectional Studies</topic><topic>Dementia</topic><topic>Dementia disorders</topic><topic>Disease Progression</topic><topic>Humans</topic><topic>Intermediate Filaments - metabolism</topic><topic>Medical prognosis</topic><topic>Movement disorders</topic><topic>Neurodegeneration</topic><topic>Neurodegenerative diseases</topic><topic>neurofilament light chain protein</topic><topic>NfL</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson Disease - diagnosis</topic><topic>Parkinson's disease</topic><topic>Plasma</topic><topic>prognosis</topic><topic>Regression analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aamodt, Whitley W.</creatorcontrib><creatorcontrib>Waligorska, Teresa</creatorcontrib><creatorcontrib>Shen, Junchao</creatorcontrib><creatorcontrib>Tropea, Thomas F.</creatorcontrib><creatorcontrib>Siderowf, Andrew</creatorcontrib><creatorcontrib>Weintraub, Daniel</creatorcontrib><creatorcontrib>Grossman, Murray</creatorcontrib><creatorcontrib>Irwin, David</creatorcontrib><creatorcontrib>Wolk, David A.</creatorcontrib><creatorcontrib>Xie, Sharon X.</creatorcontrib><creatorcontrib>Trojanowski, John Q.</creatorcontrib><creatorcontrib>Shaw, Leslie M.</creatorcontrib><creatorcontrib>Chen‐Plotkin, Alice S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aamodt, Whitley W.</au><au>Waligorska, Teresa</au><au>Shen, Junchao</au><au>Tropea, Thomas F.</au><au>Siderowf, Andrew</au><au>Weintraub, Daniel</au><au>Grossman, Murray</au><au>Irwin, David</au><au>Wolk, David A.</au><au>Xie, Sharon X.</au><au>Trojanowski, John Q.</au><au>Shaw, Leslie M.</au><au>Chen‐Plotkin, Alice S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov Disord</addtitle><date>2021-12</date><risdate>2021</risdate><volume>36</volume><issue>12</issue><spage>2945</spage><epage>2950</epage><pages>2945-2950</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><abstract>ABSTRACT
Background
Neurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration.
Objectives
To determine whether plasma and CSF NfL (1) associate with motor or cognitive status in Parkinson's disease (PD) and (2) predict future motor or cognitive decline in PD.
Methods
Six hundred and fifteen participants with neurodegenerative diseases, including 152 PD and 200 healthy control participants, provided a plasma and/or cerebrospinal fluid (CSF) NfL sample. Diagnostic groups were compared using the Kruskal−Wallis rank test. Within PD, cross‐sectional associations between NfL and Unified Parkinson's Disease Rating Scale Part III (UPDRS‐III) and Mattis Dementia Rating Scale (DRS‐2) scores were assessed by linear regression; longitudinal analyses were performed using linear mixed‐effects models and Cox regression.
Results
Plasma and CSF NfL levels correlated substantially (Spearman r = 0.64, P < 0.001); NfL was highest in neurocognitive disorders. PD participants with high plasma NfL were more likely to develop incident cognitive impairment (HR 5.34, P = 0.005).
Conclusions
Plasma NfL is a useful prognostic biomarker for PD, predicting clinical conversion to mild cognitive impairment or dementia. © 2021 International Parkinson and Movement Disorder Society</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>34480363</pmid><doi>10.1002/mds.28779</doi><tpages>30</tpages><orcidid>https://orcid.org/0000-0003-0766-1496</orcidid><orcidid>https://orcid.org/0000-0002-5599-5098</orcidid><orcidid>https://orcid.org/0000-0003-0633-7168</orcidid><orcidid>https://orcid.org/0000-0001-8130-2809</orcidid><orcidid>https://orcid.org/0000-0002-3387-2038</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3185 |
| ispartof | Movement disorders, 2021-12, Vol.36 (12), p.2945-2950 |
| issn | 0885-3185 1531-8257 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8688198 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Biomarkers Biomarkers - cerebrospinal fluid Cerebrospinal fluid Cognition Cognitive ability Cognitive Dysfunction - cerebrospinal fluid Cognitive Dysfunction - diagnosis Cognitive Dysfunction - etiology Cross-Sectional Studies Dementia Dementia disorders Disease Progression Humans Intermediate Filaments - metabolism Medical prognosis Movement disorders Neurodegeneration Neurodegenerative diseases neurofilament light chain protein NfL Parkinson Disease - complications Parkinson Disease - diagnosis Parkinson's disease Plasma prognosis Regression analysis |
| title | Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T11%3A58%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurofilament%20Light%20Chain%20as%20a%20Biomarker%20for%20Cognitive%20Decline%20in%20Parkinson%20Disease&rft.jtitle=Movement%20disorders&rft.au=Aamodt,%20Whitley%20W.&rft.date=2021-12&rft.volume=36&rft.issue=12&rft.spage=2945&rft.epage=2950&rft.pages=2945-2950&rft.issn=0885-3185&rft.eissn=1531-8257&rft_id=info:doi/10.1002/mds.28779&rft_dat=%3Cproquest_pubme%3E2569373005%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5099-9738a61298abdb667080dbf71cf82364a2e5ff98d53c4bc0a9191e0f1cb4cd4c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2611023769&rft_id=info:pmid/34480363&rfr_iscdi=true |